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Background: Elevated cardiac troponin I (cTnI) occurs in acute coronary syndrome (ACS) as well as various
scenarios not associated with ACS.
Hypothesis: Simple clinical criteria can reliably exclude ACS among hospitalized patients with elevated cTnI.
Methods: Records for patients hospitalized from January to April 2011 with elevated cTnI (>0.29 ng/dL) and
an available echocardiogram were retrospectively reviewed. Patients with ST-segment elevation myocardial
infarction were excluded. Based on available clinical data, patients were classiﬁed as having ACS or elevation
of cTnI unrelated to ACS (non-ACS). Median follow-up was 365 days.
Results: Of 265 records meeting inclusion criteria, 82 (31%) had ACS and 183 (69%) had non-ACS. In
multivariable analysis, odds ratios for non-ACS were 7.6 (95% conﬁdence interval [CI]: 3.8-15.3) for peak cTnI
<2 ng/dL, 6.3 (95% CI: 3.1-13.0) for absent wall-motion abnormality, and 4.4 (95% CI: 2.2-8.6) for no prior
coronary artery disease history. The area under the receiver operating curve for amodel using these 3 variables
was 0.86, with a 98% negative predictive value for excluding ACS. Patients who met these 3 criteria had no
ACS-related deaths over 1-year follow-up.
Conclusions: HospitalizedpatientswithpeakTn level<2ng/dL, noprior historyof coronaryarterydisease, and
no new echocardiographic wall-motion abnormality appear to have a very low likelihood of ACS. Prospective
validation of these results is needed to determine whether additional diagnostic testing could be safely
avoided in hospitalized patients meeting these simple clinical criteria.
Introduction
Cardiac troponin I (cTnI) is a sensitive and specific marker
of myonecrosis, but it is not by itself diagnostic of acute
coronary syndrome (ACS) or myocardial infarction.1 The
European Society of Cardiology/American College of Car-
diology Foundation/American Heart Association/World
Heart Federation (ESC/ACC/AHA/WHF) Task Force
statement differentiates between myocyte damage caused
by acute coronary arterial plaque rupture (type 1 acute
myocardial infarction [AMI], or ACS) and myocyte injury
from increasedmyocardial oxygen demand with inadequate
supply causing elevated serum cTnI (type 2 AMI).2,3 A
variety of clinical conditions cause cTnI elevation, including
hypotension, anemia, decompensated heart failure, myo- or
pericarditis, pulmonary embolism, sepsis, and cardiac defib-
rillator discharge.4–6 Hospitalized patients are frequently
found to have elevated cTnI of unclear significance. In the
absence of typical angina or ischemic electrocardiographic
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(ECG) changes, this common scenario presents a diagnostic
dilemma.
Echocardiography aids in the diagnosis of myocardial
ischemia and assessment of risk among patients presenting
with chest pain7–12; however, the utility of echocardio-
graphic imaging is less well-defined among the broader
population of hospitalized patients with elevated cTnI.
There is substantial clinical importance in discriminating
ACS (type 1 AMI) from other causes of elevated cTnI. The
aim of this study was to determine whether simple clinical
data, potentially including the absence of a new regional
wall-motion abnormality (WMA) on echocardiography, can
reliably exclude the diagnosis of ACS among hospitalized
patients with elevated cTnI.
Methods
Patients
Consecutive adult patients hospitalized at the University
of Michigan Health Systems from January through April
2011 were retrospectively reviewed. Inpatients with elevated
cTnI (>0.29 ng/dL) and an echocardiogram performed
during the same hospitalization were identified using an
electronic search algorithm. Patients were included if
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the echocardiogram was sufficient for analysis and was
performed within 48 hours following the initial elevated
cTnI. Patients were excluded from analysis in the setting
of ST-segment elevation myocardial infarction (STEMI),
elevated cTnI following coronary artery bypass surgery
(CABG) or percutaneous coronary intervention (PCI), or if
admission followed initial management at another hospital.
The University of Michigan Institutional Review Board
approved this study.
Biochemical Analysis
Blood samples were analyzed for cTnI per standard labo-
ratory protocol using the ADVIA Centaur immunoanalyzer
(Siemens Healthcare Diagnostics Inc., Tarrytown, NY). In
our hospital, cTnI >0.29 ng/dL is considered significant
and reliable based on the 10% coefficient of variation of
the analyzers in our laboratory. No stored blood samples
were used.
Clinical Data
Demographic data and past medical history were obtained
from the admission history and physical examination. A
history of coronary artery disease (CAD) was defined as a
stated or retrievable history of myocardial infarction (MI),
PCI, or CABG, or documentation of a significant stenosis
(>70%) on prior coronary angiography. Histories of hyper-
tension, hyperlipidemia, diabetes mellitus, atrial fibrillation,
peripheral vascular occlusive disease, cerebrovascular acci-
dent, tobacco use, and family history of CAD were based
on the available documented past medical history. End-
stage renal disease was defined as requirement for dialysis
during the index hospitalization. History of aortic stenosis
or left ventricular (LV) systolic dysfunction was based on
either documentation in the past medical history or on prior
echocardiogram.
The clinical presentation and symptoms that prompted
the clinician to order cTnI were analyzed by reviewing the
admission history and physical examination, daily progress
notes, and cardiology consultation notes, if applicable.
Symptoms were characterized as typical in nature if
recorded as substernal chest pain or pressure with exertion
or at rest, and not associated with a documented noncardiac
cause such as musculoskeletal pain.
Electrocardiograms from the time period of the elevated
cTnI were reviewed. Interpretations were based on the final
analysis of the interpreting clinical cardiologist. Analyzed
laboratory data included cTnI and serum creatinine. The
change in cTnI (cTnI) was defined as the absolute
difference between the highest and initial cTnI values.
Serum creatinine level was measured at the same time
as the initial cTnI.
Echocardiographic findings were taken from the clinical
analysis performed at the time of hospitalization. Analyzed
data included left ventricular ejection fraction (LVEF),
right ventricular function, moderate or severe pulmonary
hypertension, moderate or severe aortic stenosis, and other
severe valvular disease, all defined by overall impression in
the clinical echocardiography/Doppler report. Any regional
LV WMA was recorded as described in the final clinical
report. If aWMAwas described as old, scarred, or consistent
with a prior MI, it was classified as an old WMA rather
than a new WMA. A new regional WMA was defined
as hypokinesis, akinesis, or dyskinesis of ≥1 LV wall
segments, not documented by a previous echocardiogram
in the University of Michigan Health System.
Follow-up occurred 18 to 22 months after index
hospitalization. All records (including hospitalizations,
outpatient visits, and phone notes) were reviewed (A.D.).
Mortality outcomes were classified as related to ACS or not.
Deﬁnition of Acute Coronary Syndrome
Each patient was classified as having had either ACS
(type 1 AMI) or non-ACS using the established criteria
from the ESC/ACCF/AHA/WHF Universal Definition.3
Classification was based on detailed chart review by 2
authors (M.D., A.S.), which included the clinical scenario,
discharge diagnosis, and impressions of the treating
physicians and the consulting cardiologist, when applicable.
In the event of any uncertainty, the recordswere reviewedby
a third cardiologist (D.B.), and a diagnosis was determined
by consensus. The term ‘‘ACS’’ was used to characterize
patients believed to have had an AMI related to a thrombotic
or thromboembolic occlusion of coronary blood flow (ie,
type 1 AMI). All other clinical scenarios were categorized
as non-ACS.
Statistical Analysis
Standard statistical methods were used to compare the
characteristics of patients diagnosed with ACS to those
without ACS. Laboratory data were evaluated as continuous
or dichotomous variables, as appropriate. For clinical utility,
dichotomization of peak serumTn level occurred at 2 ng/dL.
Between-group comparisons were performed using either
the Student t test or theMann-WhitneyU test for parametric
and nonparametric data, respectively. Continuous variables
were summarized using mean± standard deviation (SD)
and/or median± interquartile range if the variables showed
a large amount of skewness. Categorical data were
compared with the likelihood ratio χ2 test. Univariable
logistic regression analyses were performed. Variables were
chosen based on their known clinical significance and
ease of use. Low level of peak Tn <2 ng/dL, absence
of a new WMA on echocardiogram, and past history of
CAD were entered into a multivariable logistic regression
model and odds ratios (OR) were generated. A receiver
operating characteristic (ROC) curve was created, and the
area under the curve (AUC) was calculated. The logistic-
regression model was validated using bootstrap resampling
to ensure that the model could be applied to new patients.13
Statistical analyses were performed using SAS version 9.2
(SAS Institute Inc., Cary, NC), validation was performed
using R-2.15.1, and follow-up analysis used SPSS version
20.0.0.1 (IBM Corp., Armonk, NY).
Results
Of 265 records meeting inclusion criteria among 260
patients, 82 (31%) had cTnI elevation related to ACS and
183 (69%) had cTnI elevation from a non-ACS cause.
Demographic data are shown in Table 1. Patients diagnosed
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Table 1. Clinical Demographics and the Diagnosis of ACS
Total, n= 265 ACS, n= 82 Non-ACS, n= 183 P Valuea
Age, y, mean (SD)/median 63 (17)/64 67.8 (13.7)/70 61.4 (18.1)/63 0.0047
Male sex, n (%) 151 (57) 49 (60) 102 (56) 0.51
BMI, kg/m2, mean (SD)/median 29.9 (9.2)/28.4 30.0 (8.1)/28.6 29.9 (9.7)/28.2 0.93
Race, n (%)
Caucasian 215 (81) 70 (85) 145 (80) 0.23
African American 32 (12) 7 (9) 25 (14) 0.24
Other 15 (6) 4 (5) 11 (6) 0.71
Hypertension, n (%) 177 (66) 61 (74) 116 (63) 0.066
Diabetes mellitus, n (%) 89 (33) 37 (45) 52 (28) 0.008
Hyperlipidemia, n (%) 125 (47) 50 (61) 75 (41) 0.002
Family history, n (%) 77 (29) 31 (38) 46 (25) 0.036
Tobacco history, n (%) 146 (55) 52 (63) 94 (51) 0.061
PVOD, n (%) 32 (12) 16 (20) 16 (9) 0.016
CVA, n (%) 19 (7) 5 (6) 14 (8) 0.65
ESRD, n (%) 22 (8) 7 (8) 15 (8) 0.92
CAD history, n (%) 107 (40) 51 (62) 56 (30) <0.0001
PCI/CABG, n (%) 75 (28) 38 (46) 37 (20) <0.0001
LV dysfunction, LVEF <55%, n (%) 32 (12) 12 (15) 20 (11) 0.39
Atrial ﬁbrillation, n (%) 49 (18) 6 (7) 43 (23) 0.0008
Aortic stenosis (moderate/severe), n (%) 14 (5) 4 (4) 10 (5) 0.85
Abbreviations: BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CVA, cerebrovascular accident; ESRD,
end-stage renal disease; LV, left ventricular; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; PVOD, peripheral vascular
occlusive disease; SD, standard deviation.
aP value for between-group comparisons.
with ACS were older. There were no significant differences
between groups in gender, body mass index, or race.
Patients classified as non-ACS were further categorized by
the clinical diagnosis presumed responsible for the elevated
cTnI (Figure 1).
Clinical data are shown in Table 2. Typical angina was
present in 10% of the total population with elevated cTnI vs
28% of patients with ACS. Themajority of ECG findings were
nonspecific or inconclusive. Among patients diagnosed with
ACS, 51% had ST-segment or T-wave changes consistent
with regional ischemia, and 12% had no evidence of ischemia
by ECG. A normal ECG was not predictive of either ACS
or non-ACS. Mean serum Tn levels (initial, peak, and )
were significantly lower in the non-ACS group (Table 2,
Figure 2).
Echocardiographic data revealed that a new WMA was
significantly more common among patients diagnosed
with ACS (52%) compared with non-ACS patients (14%;
P < 0.0001) (Table 2). The presence of moderate or severe
pulmonary hypertension or right ventricular (RV) systolic
dysfunction was more common among patients with non-
ACS (P = 0.009).
Relatively few patients underwent stress testing (31
[12%]) or cardiac catheterization (58 [22%]) during hos-
pitalization. Among those who underwent catheteriza-
tion, 45 (78%) had ACS and 13 (22%) had non-ACS.
Revascularization (PCI or CABG referral) occurred in 34
(59%) of the ACS patients and in 2 (3%) of those with
non-ACS.
Predictors of Acute Coronary Syndrome
A newWMA on echocardiography had a negative predictive
value of 80% and positive predictive value of 63% for the
identification of ACS. Variables entered into multivariable
logistic regression analysis included: (1) peak cTnI <2
ng/dL, (2) absent new WMA by echocardiogram, and (3)
no prior history of CAD. The ORs for non-ACS were 7.6
(95% confidence interval [CI]: 3.8-15.3) for peak cTnI <2
ng/dL, 6.3 (95% CI: 3.1-13.0) for absent WMA, and 4.4 (95%
CI: 2.2-8.6) for no prior CAD history. The area under the
ROC curve (ROC AUC) for a model using these 3 variables
was 0.86 (Figure 3), with a 98% negative predictive value for
excluding ACS.
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Figure 1. Diagnoses of elevated troponin in patients with non-ACS. Abbreviations: ACS, acute coronary syndrome; CHF, congestive heart failure; CPR,
cardiopulmonary resuscitation; SAH, subarachnoid hemorrhage; ICH, intracranial hemorrhage; CVA, cerebrovascular accident; ICD, implantable
cardioverter deﬁbrillator.
Records of the 2 patients who met all 3 criteria but
had a diagnosis of ACS were reviewed further. Both patients
were being treated for active hematologic malignancies; one
had undergone bone marrow transplant and the other had
received chemotherapy at the time of cTnI elevation. Both
were medically managed and had no further cardiovascular
complications. Neither patient had additional cardiology
follow-up or stress testing, and both patients died later that
year from oncologic causes.
Follow-up
All-cause mortality for the whole cohort during median
follow-up of 365 days was 30.6%. Among the 81 patients
who met our proposed 3 criteria (ie, cTnI <2 ng/dL, no
WMA, no history of CAD), there were no cardiac deaths
attributed to ACS during the follow-up period (0% vs 2.2% of
the remaining cohort, P = 0.007).
Discussion
This study presents a simple derived model to reliably
exclude ACS among hospitalized patients with elevated
cTnI. Patients meeting the 3 criteria of (1) no prior history
of CAD, (2) noWMA on echocardiogram, and (3) peak cTnI
<2 ng/dL were highly unlikely to have an ACS consistent
with type 1 AMI, with 98% negative predictive value, ROC
AUC of 0.86, and no ACS-related deaths during follow-up.
This model can provide reassurance to clinicians when
confronted with a hospitalized patient with elevated cTnI,
and additional invasive testing could be prevented among
low-risk patients meeting these criteria.
This combination of factors provides a superior risk-
prediction model than each of the criteria could separately.
For example, relying solely on elevated cTnI for diagnosis of
ACS is inadequate without additional clinical information.1
When used alone to predict ACS in hospitalized patients,
prior data found that a cTnI level of 21.7 ng/dL had a
sensitivity of 78% and specificity of 44% for the detection
of ACS, with an ROC AUC of 0.63.14 Our study also found
that cTnI alone was only predictive of ACS at very high
levels (Figure 2), which is generally not clinically useful.
Therefore, in this study, peak cTnI was dichotomized at a
level of 2 ng/dL to provide a clinically meaningful cutoff.
Preexisting CAD is a well-known risk factor for future
ischemic events and has been reported to have an OR of 3.2
(95% CI: 2.17-4.71, P < 0.001) for ACS in patients presenting
with chest pain.15 EchocardiographicWMAwas shown to be
an independent predictor of AMI, death, or need for revascu-
larization, and was superior to age, sex, or the combination
of history, ECG, and cTnI level.16 Studies of echocardiog-
raphy for diagnosis or risk prediction typically occur in the
acute setting among patients presentingwith chest pain.8–12
To our knowledge, the utility and accuracy of echocardiog-
raphy among a broader population of hospitalized patients
with elevated cTnI has not been previously studied.
Existing ACS risk-prediction tools also focus on diagnosis
and risk stratification of patients presenting to emergency
departments. For example, the Time Insensitive Predictive
Instrument (TIPI), published in the early 1990s, attempted
to diagnose ACS in patients presenting with chest pain.
Seven pieces of data including age, sex, and various features
of chest pain and ECG changes predicted ACS with an ROC
of 0.88.17 Risk-prediction tools such as Thrombolysis In
Myocardial Infarction (TIMI),18 Goldman,19 and Sanchis20
are useful for prognostication among patients with ACS,
but these were not designed to differentiate among causes
of cTnI elevation. In a study that applied these tools for
prediction of a diagnosis of ACS, low risk scoreshadnegative
predictive values of 91% (TIMI), 92% (Goldman), and 92%
(Sanchis).21 Our prediction model uses only 3 pieces of
simple data, applies to a broader hospitalized population,
and has a negative predictive value of 98%.
As novel measures of high-sensitivity cTn become more
widely available, more patients can be expected to have
detectable cTn. The ability to accurately distinguish those
suffering from ACS from patients with other causes of
cTn elevation is critical.22 Recent algorithms using high-
sensitivity cTn show promise for distinguishing AMI
from noncoronary causes.23–25 Our study demonstrates
that diagnostic algorithms should also be developed for
hospitalized patients, who frequently lack the typical signs
and symptoms of coronary ischemia.
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Table 2. Clinical Presentation, Laboratory, Electrocardiographic, and Echocardiographic Data
Total, n = 265 ACS, n = 82 Non-ACS, n = 183 P Valuea
Symptoms, n (%)
Typical angina 27 (10) 23 (28.0) 4 (2.2) <0.0001
Intubated/sedated 44 (16.6) 3 (3.7) 41 (22.4) 0.0002
Atypical 41 (15.5) 21 (25.6) 20 (10.9) 0.0023
Dyspnea 43 (16.2) 8 (9.8) 35 (19.1) 0.056
Asymptomatic 15 (5.7) 5 (6.1) 10 (5.5) 0.84
Mental status change 15 (5.7) 5 (6.1) 10 (5.5) 0.84
Tachycardia 7 (2.6) 1 (1.2) 6 (2.3) 0.33
Cardiac arrest 8 (3.0) 1 (1.2) 7 (3.8) 0.25
Syncope 6 (2.3) 3 (3.7) 3 (1.6) 0.31
Stroke 4 (1.5) 2 (2.4) 2 (1.1) 0.41
Tn level, ng/dL
Initial Tn, median (IQR) 0.9 (0.4–3.0) 3.0 (0.9–10.8) 0.6 (0.4–1.6) <0.0001
Peak Tn, median (IQR) 1.6 (0.6–8.1) 11.0 (3.1–35.2) 1.0 (0.5–2.6) <0.0001
Tn, median (IQR) 0.1 (0–2.3) 2.6 (0.4–16.1) 0 (0–0.5) <0.0001
Creatinine, mg/dL, mean (SD) 1.9 (1.8) 1.8 (1.8) 2.0 (1.8) 0.28
Electrocardiography (ECG), n (%)
No ischemic changes 40 (15) 10 (12.2) 30 (16.3) 0.38
Regional ST-T wave changes 71 (27) 42 (51.2) 29 (15.8) <0.0001
Echocardiography, normal, n (%) 84 (32) 15 (18.3) 69 (37.5) 0.0013
Mean LVEF, %, (SD)/median 49.5 (18.7)/55 45.2 (16.9)/50 51.4 (19.2)/60 0.018
LV dysfunction, n (%) 73 (27) 26 (31.7) 47 (25.5) 0.3
RV dysfunction, n (%) 54 (20) 9 (11) 45 (24.5) 0.0086
Pulmonary hypertension, n (%) 30 (11) 3 (3.7) 27 (14.7) 0.0087
Aortic stenosis, moderate/severe, n (%) 21 (8) 7 (8.5) 14 (7.6) 0.797
Other severe valve disease, n (%) 18 (7) 2 (2.4) 16 (8.7) 0.0409
Old WMA, n (%) 17 (6) 11 (13.4) 6 (3.3) 0.003
WMA, n (%) 69 (26) 43 (52.4) 25 (13.6) <0.0001
Anterior 21 (8) 17 (20.7) 4 (2.2) <0.0001
Lateral 15 (6) 12 (14.6) 3 (1.6) <0.0001
Posterior 26 (10) 20 (24.4) 6 (3.3) <0.0001
Inferior 40 (15) 26 (31.7) 14 (7.6) <0.0001
Septal 33 (12) 21 (25.6) 12 (6.5) <0.0001
Apical 29 (11) 18 (22.0) 11 (6.0) 0.0002
Takotsubo 1 (0.4) 0 (0) 1 (0.5) NS
Abbreviations: ACS, acute coronary syndrome; IQR, interquartile range; LV, left ventricular; LVEF, left ventricular ejection fraction; NS, not signiﬁcant; RV,
right ventricular; SD, standard deviation; Tn, troponin; WMA, wall-motion abnormality.
aP value for between-group comparisons.
Clin. Cardiol. 37, 7, 395–401 (2014) 399
M. Davis et al: Reliable exclusion of ACS
Published online in Wiley Online Library (wileyonlinelibrary.com)
DOI:10.1002/clc.22263© 2014 Wiley Periodicals, Inc.
Figure 2. Probability of ACS (type 1 myocardial infarction) with increasing
level of troponin. Abbreviations: ACS, acute coronary syndrome.
Figure 3. Receiver operator curves for individual variables (peak cTn <2
ng/dL, no new echocardiographic WMA, no history of CAD) and combined
variables in the discrimination of ACS among hospitalized patients with
elevated cTn. Abbreviations: ACS, acute coronary syndrome; CAD,
coronary artery disease; cTn, cardiac troponin; WMA, wall-motion
abnormality.
Elevated cTn, regardless of etiology, has been associated
with worse outcomes.26–28 The short- and long-term
management of patients with non-ACS is not well-defined,
and future research is needed to determine the optimal
management of patients with elevated cTn unrelated to ACS.
Study Limitations
This was a retrospective study and therefore subject
to bias and confounding that may have influenced our
results. However, each chart was carefully reviewed with
detailed data extraction, and consensus was reached on the
characterization of the clinical events during hospitalization.
The cTnI measurements were analyzed in a dichotomous
fashion; although this allowed for greater simplicity as a
bedside prediction tool, the model may have been more
refined by including cTnI as a continuous variable. The
Tn also may be an important tool for distinguishing
ACS from non-ACS causes, but, due to the retrospective
nature of this study, there was insufficient standardization in
timing of Tn measurements to include this in our prediction
model. Multivariate modeling was performed, but residual
unmeasured confounders may exist. The retrospective
nature of this review reflected typical practice. Of note,
patients underwent echocardiography at the discretion of
the treating clinicians; thus, if patients clearly had a non-
ACS cause of Tn elevation, an echocardiogram may not
have been performed and was not included in our study.
The results of our study should not in any way replace
good clinical judgment. Few patients underwent additional
stress testing and cardiac catheterization. Additional testing
may have provided a gold standard for comparison, but
many patients in this study had relative contraindications
for invasive catheterization. Furthermore, the presence of
obstructive coronary disease does not necessarily lead to a
diagnosis of type 1 AMI.1
Our study represents a first step in ruling out ACS (type
1 plaque rupture) among hospitalized patients, but addi-
tional tools for distinguishing demand-type ischemia vs
mechanical Tn release (such as cardiopulmonary resusci-
tation, implantable cardioverter-defibrillator placement, and
radiofrequency ablation procedures) would also be useful
areas of future research in a larger study.
Conclusion
To our knowledge, this is the first model to predict the
presence or absence of ACS among hospitalized patients
with elevated cTnI. Patients who have (1) no history of CAD,
(2) a peak cTnI<2ng/dL, and (3) nonewechocardiographic
WMA appear to have a very low likelihood of ACS.
Prospective validation of this model in an independent
sample of larger size is warranted.
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